^
Association details:
| Biomarker: | CD19 positive |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | YT-19 (CD19 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
270 A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL)
Published date:
11/04/2020
Excerpt:
The Phase I first-in-human study demonstrated technical feasibility, clinical safety and efficacy of STAR-T in treating CD19+ R/R B-ALL. A high CR could be achieved on day 14 with low toxicity.
Trial ID:
